| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Bayesian Quantitative Disease–Drug–Trial Models for Parkinson’s Disease to Guide Early Drug Development
|
Lee, Joo Yeon
|
|
2011
|
13 |
4 |
p. 508-518
|
article
|
| 2 |
BDDCS Applied to Over 900 Drugs
|
Benet, Leslie Z.
|
|
2011
|
13 |
4 |
p. 519-547
|
article
|
| 3 |
Bilirubin—A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy
|
Rekić, Dinko
|
|
2011
|
13 |
4 |
p. 598-605
|
article
|
| 4 |
Biomarkers for Drug-Induced Renal Damage and Nephrotoxicity—An Overview for Applied Toxicology
|
Fuchs, Tobias Christian
|
|
2011
|
13 |
4 |
p. 615-631
|
article
|
| 5 |
Comparative Performance of Cell Life Span and Cell Transit Models for Describing Erythropoietic Drug Effects
|
Budha, Nageshwar R.
|
|
2011
|
13 |
4 |
p. 650-661
|
article
|
| 6 |
Differential Metabolism of Organic Nitrates by Aldehyde Dehydrogenase 1a1 and 2: Substrate Selectivity, Enzyme Inactivation, and Active Cysteine Sites
|
Tsou, Pei-Suen
|
|
2011
|
13 |
4 |
p. 548-555
|
article
|
| 7 |
Epigenetic CpG Demethylation of the Promoter and Reactivation of the Expression of Neurog1 by Curcumin in Prostate LNCaP Cells
|
Shu, Limin
|
|
2011
|
13 |
4 |
p. 606-614
|
article
|
| 8 |
Erratum to: Modeling the Effects of Vaccination and Treatment on Pandemic Influenza
|
Feng, Zhilan
|
|
2011
|
13 |
4 |
p. 674
|
article
|
| 9 |
Factors Influencing the Use and Interpretation of Animal Models in the Development of Parenteral Drug Delivery Systems
|
Martinez, Marilyn N.
|
|
2011
|
13 |
4 |
p. 632-649
|
article
|
| 10 |
Harmonization of Regulatory Approaches for Evaluating Therapeutic Equivalence and Interchangeability of Multisource Drug Products: Workshop Summary Report
|
Chen, Mei-Ling
|
|
2011
|
13 |
4 |
p. 556-564
|
article
|
| 11 |
Holford NHG and Sheiner LB “Understanding the Dose-Effect Relationship-Clinical Application of Pharmacokinetic-Pharmacodynamic Models”, Clin Pharmacokin 6:429–453 (1981)—The Backstory
|
Holford, Nick
|
|
2011
|
13 |
4 |
p. 662-664
|
article
|
| 12 |
Optimal Design in Population Kinetic Experiments by Set-Valued Methods
|
Gennemark, Peter
|
|
2011
|
13 |
4 |
p. 495-507
|
article
|
| 13 |
Pharmacodynamic Model of Sodium–Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational Pharmacology
|
Maurer, Tristan S.
|
|
2011
|
13 |
4 |
p. 576-584
|
article
|
| 14 |
Population Pharmacokinetics of Telapristone (CDB-4124) and its Active Monodemethylated Metabolite CDB-4453, with a Mixture Model for Total Clearance
|
Morris, Denise
|
|
2011
|
13 |
4 |
p. 665-673
|
article
|
| 15 |
Quantitative PK–PD Model-Based Translational Pharmacology of a Novel Kappa Opioid Receptor Antagonist Between Rats and Humans
|
Chang, Cheng
|
|
2011
|
13 |
4 |
p. 565-575
|
article
|
| 16 |
Relationships between Liposome Properties, Cell Membrane Binding, Intracellular Processing, and Intracellular Bioavailability
|
Li, Yinghuan
|
|
2011
|
13 |
4 |
p. 585-597
|
article
|
Journal description